Pharmacologic modulation strategies to reduce dose requirements of anticancer therapy while preserving clinical efficacy. (June 2012)

• Record Type: Journal Article
• Authors: Zee, Ying-Kiat; Goh, Boon-Cher; Lee, Soo-Chin
• Is Part Of: Future oncology. Volume 8:Number 6(2012)
• Page Start: 731
• Page End: 749
• Publication Date: 2012-06
• Subjects: drug interactions -- drug-metabolizing enzymes -- drug transporters -- inducers -- inhibitors -- pharmacokinetic interactions -- pharmacologic modulation; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.12.53
• Languages: English
• ISSNs: 1479-6694

Abstract

Drug interactions may be exploited to overcome pharmacokinetic issues in order to improve the therapeutic index of a drug, with clinical goals of reducing the dose of the active drug while preserving efficacy or reducing toxicity. This strategy has been used in infectious disease and transplant medicine, and, more recently, in oncology. Pharmacologic modulation strategies range from coadministration of either a drug that inhibits a metabolizing enzyme that would inactivate the drug of interest, a drug that induces an enzyme that activates the drug of interest or a drug that inhibits transporters that affect the uptake or elimination of the drug of interest. This review will discuss pharmacologic modulation strategies that have been tested clinically in order to increase systemic drug exposure. Important examples include ketoconazole inhibition of hepatic CYP3A4 in order to increase systemic exposure to docetaxel, irinotecan and etoposide, and cyclosporine inhibition of intestinal ATP-binding cassette transporters in order to decrease the toxicity of irinotecan and increase the bioavailability of oral docetaxel, paclitaxel and topotecan.